Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)
Launched by NOVARTIS · May 18, 2007
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have completed the core CCOX189A2360 study
- • Males and females over the 18 years old
- Exclusion Criteria:
- • Treatment in the extension study is not considered appropriate by the treating physician
- • Non-compliance or major protocol violation of the core study
- • Other protocol-defined inclusion/exclusion criteria may apply
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Tucson, Arizona, United States
Albuquerque, New Mexico, United States
Sioux Falls, South Dakota, United States
Tucson, Arizona, United States
Albuquerque, New Mexico, United States
Sioux Falls, South Dakota, United States
Brampton, Ontario, Canada
Brooklyn Park, Minnesota, United States
San Antonio, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials